Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-207

RC110 data is advanced and robust. If a license deal were to happen with our friends at Astex, I would expect this to drop before 2nd November or AGM.

Abbvie is a dark horse and fresh off the block so may be 3 months post ASH. Otherwise another unknown player between now and 30th June.

If extending beyond this I would not be holding my breath. Just speculation, as a deal may or may not happen, we are ‘fully funded’ for this program.

But if a deal is struck biobucks and funding can be redirected to other programs.